Universitäres Centrum für Tumorerkrankungen Mainz (UCT Mainz)
Klinisch orientierter Schwerpunkt / Johannes Gutenberg-Universität Mainz
Paret, Claudia; Lehmann, Nadine; Bender, Hannah et al.
Identification of an Immunogenic Medulloblastoma-Specific Fusion Involving EPC2 and GULP1CANCERS. Bd. 13. H. 22. 2021
Guel, Desiree; Habtemichael, Negusse; Dietrich, Dimo et al.
Identification of cytokeratin24 as a tumor suppressor for the management of head and neck cancerBIOLOGICAL CHEMISTRY. Bd. 403. H. 8-9. 2021 S. 869-890
Marron, Manuela; Brackmann, Lara Kim; Schwarz, Heike et al.
Identification of Genetic Predispositions Related to Ionizing Radiation in Primary Human Skin Fibroblasts From Survivors of Childhood and Second Primary Cancer as Well as Cancer-Free Controls: Protocol for the Nested Case-Control Study KiKmeJMIR RESEARCH PROTOCOLS. Bd. 10. H. 11. 2021
Ducreux, Michel; Zhu, Andrew X.; Cheng, Ann-Lii et al.
IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor).JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Zhu, Andrew X.; Finn, Richard; Ducreux, Michel et al.
IMbrave150: EXPLORATORY EFFICACY AND SAFETY OF ATEZOLIZUMAB (ATEZO) plus BEVACIZUMAB (BEV) VS SORAFENIB (SOR) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WITH NON-VIRAL ETIOLOGY IN A GLOBAL PHASE III STUDYHEPATOLOGY. Bd. 74. 2021 S. 646A-647A
Breder, Valeriy Vladimirovich; Vogel, Arndt; Merle, Philippe et al.
IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Finn, Richard S.; Qin, Shukui; Ikeda, Masafumi et al.
IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)SWISS MEDICAL WEEKLY. Bd. 151. 2021 S. 25-26
Finn, Richard S.; Qin, Shukui; Ikeda, Masafumi et al.
IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC).CANCER RESEARCH. Bd. 81. H. 13. 2021
Galle, P.; Finn, R. S.; Qin, S. et al.
IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)ONCOLOGY RESEARCH AND TREATMENT. Bd. 44. 2021 S. 34-34
Heimes, AK; Schmidt, M
Immuno-oncology in triple-negative breast cancerJ Cancer Metastasis Treat. Bd. 7. 2021 S. 9